For women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall and progression-free survival, according to a study ...
Jun 2, 2023
0
5
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 ...
Apr 17, 2023
0
75
The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared to immunotherapy alone, a new clinical trial shows.
Apr 16, 2023
0
67
For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The Lancet ...
Mar 13, 2023
0
6
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who ...
Mar 1, 2023
0
12
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who ...
Sep 11, 2022
0
39
Long-term follow up of patients with extensive stage small cell lung cancer who were given pembrolizumab and etoposide/platinum (EP) versus placebo + etoposide/platinum as first-line therapy support the continued exploration ...
Aug 9, 2022
0
7
Matching cancer patients to treatment based on their levels of a key immune protein may allow doctors to select those who would benefit most from the combination of immunotherapy and chemotherapy, researchers report.
Mar 28, 2022
0
71
A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.
Mar 1, 2022
0
39
An immunotherapy drug called pembrolizumab has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by ...
Feb 10, 2022
0
13
